Amyris Biotechnologies Secures Investment from Temasek Holdings

According to the Amyris Press Release, “Amyris Biotechnologies, Inc. announced today that Temasek Holdings has invested $47.8 million into the company. Amyris intends to use these funds to support commercial plant design and construction activities as well as ongoing operations in the U.S. and Brazil.

“We are privileged to welcome Temasek as a significant investor, and appreciate having them join us as we look to commercialize and scale our renewable fuels and chemicals,” said John Melo, chief executive officer of Amyris.

Amyris has secured $244 million in private funding since inception in 2003, including funding directly into Amyris Biotechnologies and into its subsidiary, Amyris Brasil S.A. Other Amyris investors include Kleiner Perkins Caufield & Byers, Khosla Ventures, TPG Biotechnology, Votorantim Novos Negocios, Advanced Equities Inc., DAG Ventures, Grupo Cornélio Brennand, Naxos U.K., The Westly Group, and Stratus Group.”

read more: Amyris

Contact the writer or creator of this article or page.
Questions or comments: support(at)swfinstitute(dot)org
Follow on Twitter at @swfinstitute and @sovereignfunds
Learn, Attend and Network: Institutional Investor Events and Summits
Go Back: HOME: Sovereign Wealth Fund Institute

institutional investor investment mandates